ARMO, Backed by China Investors, Completes $128 Million IPO in US
publication date: Jan 26, 2018
ARMO BioSciences, a Bay Area immuno-oncology company, completed a $128 million IPO on the Nasdaq exchange. The shares rose 75% on the first day to close at $29.74. In its Series C-1 funding, completed in August 2017, ARMO raised $67 million led by China investor Qiming Ventures, and joined by new China investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments. ARMO's lead molecule is AM0010, a pegylated form of Interleukin-10, which is currently in Phase III trials as an adjunct to FOLFOX and in Phase I trials as a single agent. More details....
Stock Symbol: (NSDQ: ARMO)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.